Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
| Autor: | Michael Pfreundschuh, Wolf-Dieter Ludwig, Lorenz Trümper, Orhan Sezer, Andreas Lohri, Martin Wilhelm, Jeremy Franklin, Markus W. Löffler, Dirk Hasenclever, Andreas Engert, Walter-Erich Aulitzky, Mathias Hänel, Hans Konrad Müller-Hermelink, Mathias J. Rummel, Bernd Dörken, Volker Diehl, Peter Koch, Martin Bentz |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male BEACOPP Oncology Cancer Research medicine.medical_specialty Dacarbazine medicine.medical_treatment Vinblastine Procarbazine Bleomycin Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Aged Etoposide Dose-Response Relationship Drug business.industry Middle Aged Hodgkin's lymphoma medicine.disease Hodgkin Disease COPP Chemotherapy regimen Surgery Regimen Treatment Outcome ABVD Doxorubicin Vincristine Prednisone Female business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 27:4548-4554 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | Purpose The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) chemotherapy regimen in 1,196 patients with advanced-stage Hodgkin's lymphoma (HL). The previous analysis with 5 years median follow-up had indicated improved tumor control with BEACOPP escalated. Since the long-term safety and efficacy of this regimen has been debated, we report the 10-year follow-up. Patients and Methods Patients received one of three chemotherapy regimens: eight cycles of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) alternating with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); eight cycles of BEACOPP baseline; or eight cycles of BEACOPP escalated. Results Median follow-up was 111 months. At 10 years, freedom from treatment failure (FFTF) was 64%, 70%, and 82% with OS rates of 75%, 80%, and 86% for patients treated with COPP/ABVD (arm A), BEACOPP baseline (arm B), and BEACOPP escalated (arm C), respectively (P < .001). BEACOPP escalated was significantly better than BEACOPP baseline in terms of FFTF (P < .0001) and OS (P = .0053). A total of 74 second malignancies (6.2%) were documented, including acute myeloid leukemia (0.4%, 1.5%, and 3.0%), non-Hodgkin's lymphoma (2.7%, 1.7%, and 1.0%), and solid tumors (2.7%, 3.4%, and 1.9%). The corresponding overall secondary malignancy rates were 5.7%, 6.6%, and 6.0%, respectively. Conclusion The 10-year follow-up of the HD9 trial demonstrates a stabilized significant improvement in long-term FFTF and OS for BEACOPP escalated in advanced-stage HL. These results challenge ABVD as standard of care for this patient population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|